Outcome predictive factors in patients with sarcoidosis

Calaras, Diana; Munteanu, Oxana; Luchian, Zinaida; David, A.; Botnaru, Victor

doi:10.1183/1393003.congress-2017.pa3262

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The majority of patients with sarcoidosis have normal lung function but may also show restrictive [23,24] or obstructive patterns [1,25]. Recent evidence suggests that the dominant functional abnormality in intrathoracic sarcoidosis is obstruction, affecting the entire length of the bronchial tree and causing a wide range of airways impairment and altered gas diffusion [26]; the obstructive disturbances are present from the early stages, mainly affecting small airways, and, in advanced disease, obstructive impairment often exists with restrictive disorders. The evidence of reduction in DLCO may suggest parenchymal involvement or indicate the presence of pulmonary hypertension [27,28].…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Analysis of 2-Year Follow-Up of Patients with Incidental Findings of Sarcoidosis

Thomas-Orogan,

Barratt,

Zafran

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Introduction: Sarcoidosis is a multi-system granulomatous disease most commonly involving the lungs. It may be incidentally diagnosed during imaging studies for other conditions or non-specific symptoms. The appropriate follow-up of incidentally diagnosed asymptomatic stage 1 disease has not been well defined. Objective: To define the clinical course of incidentally diagnosed asymptomatic stage 1 sarcoidosis and propose an algorithm for the follow-up of these patients. Methodology: A retrospective case note analysis was performed of all EBUS-TBNA (endobronchial ultrasound-guided transbronchial needle aspiration)-confirmed cases of stage 1 sarcoidosis presenting incidentally to Bristol and Liverpool Interstitial Lung Disease services. Clinical history, serology results, imaging scans, and lung function parameters were examined at baseline, 12, and 24 months. A cost analysis was performed comparing the cost of the current 2-year follow-up guidance to a 1 year follow-up period. Results: Sixty-seven patients were identified as the final cohort. There was no significant change in the pulmonary function tests over the two-year follow-up period. Radiological disease stability was observed in the majority of patients (58%, n = 29), and disease regression was evidenced in 40% (n = 20) at 1 year. Where imaging was performed at 2 years, the majority (69.8%, n = 37) had radiological evidence of disease regression, and 30.2% (n = 16) showed radiological evidence of stability. All patients remained asymptomatic and did not require therapeutic intervention over the study period. Conclusions: Our results show that asymptomatic patients with incidental findings of thoracic lymph nodal non-caseating granulomas do not progress over a 2-year period. Our results suggest that the prolonged secondary-care follow-up of such patients may not be necessary. We propose that these patients are followed up for 1 year with a further year of patient-initiated follow-up (PIFU) prior to discharge.

show abstract

Section: Discussionmentioning

confidence: 99%

A Retrospective Analysis of 2-Year Follow-Up of Patients with Incidental Findings of Sarcoidosis

Thomas-Orogan,

Barratt,

Zafran

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

“…After having given written informed consent, a total of 81 patients affected by sarcoidosis were enrolled from January 2019 to December 2022. The diagnosis was made during a routine clinical assessment in our pulmonology department, a referral center for sarcoidosis [ 4 , 5 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ]. A complete medical history was collected and all patients were examined clinically.…”

Section: Methodsmentioning

confidence: 99%

“…Global spirometry values were recorded, i.e., functional vital capacity (FVC), forced expiratory volume in 1 s (FEV1), forced expiratory volume in 1 s/functional vital capacity (FEV1/FVC) ratio, also known as the Tiffeneau–Pinelli Index (IT), and diffusion capacity of carbon monoxide (DLCO). The employment of respiratory function tests in the management of patients with sarcoidosis, to date, is particularly useful for monitoring the long-term course of the disease [ 20 , 21 , 22 , 23 , 24 ].…”

Section: Methodsmentioning

confidence: 99%

Pulmonary Sarcoidosis and Immune Dysregulation: A Pilot Study on Possible Correlation

Cifaldi,

Salton,

Confalonieri

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Background: Sarcoidosis is a systemic inflammatory disease characterized by an altered inflammatory response. Objective: The aim of this study was to evaluate whether immune system alterations detected by lymphocyte typing in peripheral blood correlate with the severity of sarcoidosis, calculated according to two separate severity scores proposed by Wasfi in 2006 and Hamzeh in 2010. Materials and Methods: Eighty-one patients were recruited, and clinical data and laboratory tests at the time of diagnosis were obtained in order to assess the severity index score and investigate any statistically significant correlation with the cytofluorimetry data. Results: Our data demonstrated that none of the two scores show an association with the level of total lymphocytes or lymphocyte subclasses. Limitations: First of all, the sample taken into consideration is small. The assessment was performed only at disease onset and not during the disease. Furthermore, the severity scores do not take into account disease activity (measured by PET/CT or gallium scintigraphy). Conclusions: Lymphocyte subpopulation values at the time of diagnosis do not appear to correlate with disease severity at onset.

show abstract

“…However, an obstructive defect, which is not typically associated with fibrotic ILDs other than sarcoidosis, is also relatively common, even in patients with advanced fibrosis [15]. Diffusion capacity (Dlco) is reduced in as many as two-thirds of patients with sarcoidosis [117], variably reflecting interstitial disease and pulmonary vasculopathy [118].…”

Section: Ct Phenotypes In Sarcoidosismentioning

confidence: 99%

Imaging of Pulmonary Sarcoidosis—A Review

Bailey,

Wells,

Desai

2024

JCM

View full text Add to dashboard Cite

Sarcoidosis is the classic multisystem granulomatous disease. First reported as a disorder of the skin, it is now clear that, in the overwhelming majority of patients with sarcoidosis, the lungs will bear the brunt of the disease. This review explores some of the key concepts in the imaging of pulmonary sarcoidosis: the wide array of typical (and some of the less common) findings on high-resolution computed tomography (HRCT) are reviewed and, with this, the concept of morphologic/HRCT phenotypes is discussed. The pathophysiologic insights provided by HRCT through studies where morphologic abnormalities and pulmonary function tests are compared are evaluated. Finally, this review outlines the important contribution of HRCT to disease monitoring and prognostication.

show abstract

Outcome predictive factors in patients with sarcoidosis

Cited by 5 publications

References 0 publications

A Retrospective Analysis of 2-Year Follow-Up of Patients with Incidental Findings of Sarcoidosis

A Retrospective Analysis of 2-Year Follow-Up of Patients with Incidental Findings of Sarcoidosis

Pulmonary Sarcoidosis and Immune Dysregulation: A Pilot Study on Possible Correlation

Imaging of Pulmonary Sarcoidosis—A Review

Contact Info

Product

Resources

About